加勢田 馨

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Adenocarcinoma of Lung 54%
3. Lung 44%
4. Neoplasm Metastasis 34%
5. Retrospective Studies 34%
6. Neoplasms 33%
7. Cohort Studies 27%
8. Positron Emission Tomography Computed Tomography 27%
9. fibrin fragment D 24%
10. Fluorodeoxyglucose F18 22%
11. Tumor Microenvironment 21%
12. Lung Neoplasms 20%
13. ErbB Receptors 19%
14. Survival 18%
15. Lymph Nodes 18%
16. Recurrence 18%
17. tricarbonyldichlororuthenium (II) dimer 17%
18. Tomography 17%
19. Aldehyde Dehydrogenase 1 15%
20. Respiratory Paralysis 15%
21. Sinus Histiocytosis 15%
22. Crizotinib 14%
23. Thymoma 13%
24. Trachea 13%
25. Pneumonectomy 13%
26. Paraganglioma 12%
27. Segmental Mastectomy 12%
28. Adenocarcinoma 12%
29. Medical Oncology 12%
30. Germ Cell and Embryonal Neoplasms 11%
31. Hemoptysis 11%
32. Papilloma 11%
33. Neoadjuvant Therapy 11%
34. Arteriovenous Malformations 11%
35. Papillary Thyroid Cancer 11%
36. Carcinoid Tumor 11%
37. Mutation 11%
38. Postoperative Complications 11%
39. Leiomyoma 11%
40. Eyelids 10%
41. Carbon Monoxide 10%
42. Therapeutics 9%
43. Positron-Emission Tomography 9%
44. Multivariate Analysis 9%
45. Drug Therapy 9%
46. Anaplastic Lymphoma Kinase 9%
47. Allografts 8%
48. Lymphoma 8%
49. Air 8%
50. Diabetes Mellitus 8%